The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP–PKA–EGFR–STAT3 axis
- 20 March 2017
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 36 (29) , 4135-4149
Abstract
Epidemiological studies have demonstrated a close association of type 2 diabetes and hepatocellular carcinoma (HCC). Exenatide (Ex-4), a potent diabetes drug targeting glucagon-like peptide-1 receptor (GLP-1R), is protective against non-alcoholic fatty liver disease (NAFLD). However, the Ex-4 function and GLP-1R status have yet been explored in HCC. Herein we investigated the effect of Ex-4 in diethylnitrosamine (DEN)-treated mice consuming control or high-fat high-carbohydrate diet. Administration of Ex-4 significantly improved obesity-induced hyperglycemia and hyperlipidemia and reduced HCC multiplicity in obese DEN-treated mice, in which suppressed proliferation and induced apoptosis were confined to tumor cells. The tumor suppression effects of Ex-4 were associated with high expression of GLP-1R and activation of cyclic AMP (cAMP) and protein kinase A (PKA). Importantly, Ex-4 also downregulated epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3), which lie downstream of cAMP-PKA signaling, resulting in suppression of multiple STAT3-targeted genes including c-Myc, cyclin D1, survivin, Bcl-2 and Bcl-xl. The growth inhibitory effects of Ex-4 were consistent in GLP-1R-abundant hepatoma cell lines and xenograft mouse model, wherein both PKA and EGFR had obligatory roles in mediating Ex-4 functions. In addition, Ex-4 also effectively suppressed inflammatory and fibrotic phenotypes in mice fed with methionine–choline-deficient (MCD) diet and choline-deficient ethionine-supplemented (CDE) diet, respectively. In summary, Ex-4 elicits protective functions against NAFLD and obesity-associated HCC through cAMP-PKA-EGFR-STAT3 signaling, suggesting its administration as a novel approach to reduce HCC risk in diabetic patients.Keywords
This publication has 46 references indexed in Scilit:
- Do GLP-1–Based Therapies Increase Cancer Risk?Diabetes Care, 2013
- NAFLD in Asia—as common and important as in the WestNature Reviews Gastroenterology & Hepatology, 2013
- Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2012
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC)Medical Oncology, 2010
- GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo TargetingJournal of Nuclear Medicine, 2007
- The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic EvidenceClinical Gastroenterology and Hepatology, 2006
- The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cellsCellular Signalling, 2005
- Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activationHepatology, 2004
- Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrenceHepatology, 1999